Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Table 1 Baseline patient characteristics.

Variable	Type 2 diabetes
Age (years)^†	59
Gender (% male)^†	56%
BMI (kg/m²)^†	31.9
Weight (kg)^†	89.8
Height (metres)^†	1.67
Ethnicity (% black)^†	1%
Total cholesterol (mmol/L)^‡	5.2
HDL cholesterol (mmol/L)^‡	1.04
Systolic blood pressure (mmHg)^‡	136
HbA_1c (%)^†	7.1
Peripheral vascular disease (%)^‡	30%
Smoking (%)^‡	0
Risk of severe hypoglycaemia*	0.462
Number of nocturnal hypos (year)^†	2.4
Number of symptomatic hypos (year)^†	6.8

^†Data from Heine et al[22], ^‡ data from UKPDS baseline cohort[16], * data from Leese et al[6]

ISSN: 1475-2840